Moderna gets EMA review for Omicron BA.4/BA.5 targeting booster shot for aged 12, above

Sep. 28, 2022 5:35 AM ETModerna, Inc. (MRNA)By: Ravikash, SA News Editor25 Comments

European Union flag against European Parliament

artJazz

  • The European Medicines Agency (EMA) accepted Moderna's (NASDAQ:MRNA) application for conditional marketing authorization of a 50 µg booster dose of the Omicron-containing bivalent COVID booster vaccine mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) in adults 12 years and older.
  • Spikevax bivalent Original/Omicron BA.4-5 is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine targeting the Omicron variant BA.4/BA.5, Moderna said in a Sept. 28 press release.
  • "Following the recent approval of our BA.1 targeting vaccine in Europe, our BA.4/BA5 Omicron targeting vaccine will now bring a second option to help protect people across Europe as we head into the winter months," said Moderna CEO Stéphane Bancel.
  • MRNA +0.14% to $122.40 premarket Sept. 28

Recommended For You

Comments (25)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.